Paper of the Month
Paper of the month: Efficacy and safety of andexanet to reverse factor Xa inhibitors activity.
For February 2016 we have selected: Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;33:2413-2424.
There is an increased use of direct factor Xa inhibitors (like apixaban, rivaroxaban, and edoxaban) to prevent stroke in patients with nonvalvular atrial fibrillation since these medications have several advantages compared to vitamin K antagonists.










Background
The Alliance for MRI, a coalition of European Parliamentarians, patient groups, leading European scientists and the medical community, was officially launched in March 2007 in response to the pending implementation of the EU Physical Agents 2004/40/EC (on electromagnetic…